GEN Exclusives

More »

Sidebars

More »
Mar 15, 2009 (Vol. 29, No. 6)

Novel OncoMouse Model

  • Caliper Discovery Alliances & Services (CDAS), which offers multiple tumor models for preclinical cancer research, reports that it recently developed a pancreatic OncoMouse® model—EL1-luc/EL1-SV40 T-antigen transgenic—to overcome some disadvantages of xenograft tumor models, such as the use of immuno-compromised mice. Through a specific agreement with DuPont Intellectual Assets & Licensing (see January 1 GEN, page 16), CDAS says it can now provide preclinical in vivo compound efficacy and research studies using spontaneous tumor models linking an activated oncogene with a bioluminescent reporter system. It is now possible for scientists to study drug effects in the more relevant physiological microenvironment context of a nonimmnuno-compromised animal, which will better recapitulate the effect of the drug in humans, according to a CDAS official.


Add a comment

  • You must be signed in to perform this action.
    Click here to Login or Register for free.
    You will be taken back to your selected item after Login/Registration.

Jobs

GEN Jobs powered by HireLifeScience.com connects you directly to employers in pharma, biotech, and the life sciences. View 40 to 50 fresh job postings daily or search for employment opportunities including those in R&D, clinical research, QA/QC, biomanufacturing, and regulatory affairs.
 Searching...
More »

GEN Poll

More » Poll Results »

Companion Animal Care

Do you think Americans spend too much on companion animal care?